BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 36279204)

  • 21. National evidence on the use of shared decision making in prostate-specific antigen screening.
    Han PK; Kobrin S; Breen N; Joseph DA; Li J; Frosch DL; Klabunde CN
    Ann Fam Med; 2013; 11(4):306-14. PubMed ID: 23835816
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study.
    Carlsson S; Assel M; Ulmert D; Gerdtsson A; Hugosson J; Vickers A; Lilja H
    Eur Urol; 2017 Jan; 71(1):46-52. PubMed ID: 27084245
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostate Cancer Screening and Incidence among Aging Persons Living with HIV.
    Leapman MS; Stone K; Wadia R; Park LS; Gibert CL; Goetz MB; Bedimo R; Rodriguez-Barradas M; Shebl F; Justice AC; Brown ST; Crothers K; Sigel KM
    J Urol; 2022 Feb; 207(2):324-332. PubMed ID: 34555924
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Racial and Ethnic Disparities in Prostate Cancer Outcomes in the Veterans Affairs Health Care System.
    Yamoah K; Lee KM; Awasthi S; Alba PR; Perez C; Anglin-Foote TR; Robison B; Gao A; DuVall SL; Katsoulakis E; Wong YN; Markt SC; Rose BS; Burri R; Wang C; Aboiralor O; Fink AK; Nickols NG; Lynch JA; Garraway IP
    JAMA Netw Open; 2022 Jan; 5(1):e2144027. PubMed ID: 35040965
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate-specific antigen testing rates in high-risk populations: results from the All of Us Research Program.
    Morley F; Iyer HS; Tamimi RM; Nanus DM; Rebbeck TR; Kensler KH
    Cancer Causes Control; 2024 Mar; 35(3):509-521. PubMed ID: 37878135
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening.
    Kearns JT; Holt SK; Wright JL; Lin DW; Lange PH; Gore JL
    Cancer; 2018 Jul; 124(13):2733-2739. PubMed ID: 29781117
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low-Value Prostate-Specific Antigen Screening in Older Males.
    Kalavacherla S; Riviere P; Javier-DesLoges J; Banegas MP; McKay RR; Murphy JD; Rose BS
    JAMA Netw Open; 2023 Apr; 6(4):e237504. PubMed ID: 37040113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
    Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
    BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of Prostate-specific Antigen (PSA) Screening Trials and Revised PSA Screening Guidelines on Rates of Prostate Biopsy and Postbiopsy Complications.
    Gershman B; Van Houten HK; Herrin J; Moreira DM; Kim SP; Shah ND; Karnes RJ
    Eur Urol; 2017 Jan; 71(1):55-65. PubMed ID: 26995328
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes in Prostate Cancer Presentation Following the 2012 USPSTF Screening Statement: Observational Study in a Multispecialty Group Practice.
    Presti J; Alexeeff S; Horton B; Prausnitz S; Avins AL
    J Gen Intern Med; 2020 May; 35(5):1368-1374. PubMed ID: 31820217
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis.
    Ilic D; Djulbegovic M; Jung JH; Hwang EC; Zhou Q; Cleves A; Agoritsas T; Dahm P
    BMJ; 2018 Sep; 362():k3519. PubMed ID: 30185521
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.
    Yli-Hemminki TH; Laurila M; Auvinen A; Määttänen L; Huhtala H; Tammela TL; Kujala PM
    BJU Int; 2013 Oct; 112(6):735-41. PubMed ID: 23746332
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of Treatment With 5α-Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer.
    Sarkar RR; Parsons JK; Bryant AK; Ryan ST; Kader AK; McKay RR; D'Amico AV; Nguyen PL; Hulley BJ; Einck JP; Mundt AJ; Kane CJ; Murphy JD; Rose BS
    JAMA Intern Med; 2019 Jun; 179(6):812-819. PubMed ID: 31058923
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence.
    Hayes JH; Barry MJ
    JAMA; 2014 Mar; 311(11):1143-9. PubMed ID: 24643604
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial.
    Arnsrud Godtman R; Holmberg E; Lilja H; Stranne J; Hugosson J
    Eur Urol; 2015 Sep; 68(3):354-60. PubMed ID: 25556937
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Contemporary National Trends of Prostate Cancer Screening Among Privately Insured Men in the United States.
    Kim SP; Karnes RJ; Gross CP; Meropol NJ; Van Houten H; Abouassaly R; Shah ND
    Urology; 2016 Nov; 97():111-117. PubMed ID: 27527411
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate Cancer Screening Uptake in Transgender Women.
    Kalavacherla S; Riviere P; Kalavacherla S; Anger JT; Murphy JD; Rose BS
    JAMA Netw Open; 2024 Feb; 7(2):e2356088. PubMed ID: 38353948
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluating Prostate-Specific Antigen Screening for Young African American Men With Cancer.
    Qiao EM; Lynch JA; Lee KM; Kotha NV; Nalawade V; Voora RS; Qian AS; Nelson TJ; Yamoah K; Garraway IP; Stewart TF; Parsons JK; Rose BS
    J Natl Cancer Inst; 2022 Apr; 114(4):592-599. PubMed ID: 34893859
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Practitioner-level determinants of inappropriate prostate-specific antigen screening.
    Kerfoot BP; Holmberg EF; Lawler EV; Krupat E; Conlin PR
    Arch Intern Med; 2007 Jul; 167(13):1367-72. PubMed ID: 17620529
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Downstream tests, treatments, and annual direct payments in older men cared for by primary care providers with high or low prostate-specific antigen screening rates using 100 percent Texas U.S. Medicare public insurance claims data: a retrospective cohort study.
    Zanwar P; Lin YL; Kuo YF; Goodwin JS
    BMC Health Serv Res; 2016 Jan; 16():17. PubMed ID: 26772175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.